Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

Core Viewpoint - Bright Minds Biosciences Inc. is launching a public offering of common shares and pre-funded warrants to raise aggregate gross proceeds of US$100 million to fund clinical trials and research initiatives [1][2]. Group 1: Offering Details - The public offering includes common shares and pre-funded warrants, with a total gross proceeds target of US$100 million [1]. - The company will grant underwriters a 30-day option to purchase up to an additional 15% of the common shares issued in the offering [1]. - The offering is being conducted under a shelf registration statement that was declared effective by the SEC on September 2, 2025 [3]. Group 2: Use of Proceeds - Net proceeds from the offering will be used to fund future clinical trials for drug candidates targeting absence seizures, DEE, and Prader-Willi Syndrome [2]. - The funds will also support the initiation of phase 1 clinical trials for BMB-105 and additional research and development for earlier phase programs [2]. Group 3: Company Overview - Bright Minds is a biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders [5]. - The company has a pipeline that includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical needs, such as epilepsy and depression [5][6]. - Bright Minds has developed a unique platform of highly selective serotonergic agonists, contributing to a rich portfolio of new chemical entity programs within neurology and psychiatry [6].